The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

ADI-001 clinical development program now addresses six autoimmune diseases. Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be ...

The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

The US FDA has imposed a clinical hold on Kezar Life Sciences’ IND application for zetomipzomib, aimed at treating lupus ...

The FDA's decision comes after the company said it had paused the mid-stage trial of the drug, zetomipzomib, to review safety ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...

Fava said that the majority of patients with lupus nephritis don’t feel different than normal when they’re diagnosed and that the condition requires more aggressive treatment than for symptoms like ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...

When used in combination therapy, the dose of glucocorticoids is gradually reduced as clinical symptoms improve, significantly enhancing efficacy and ... In the LUNAR study, 144 patients with class ...